# Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

> **NCT00130507** · PHASE2 · TERMINATED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 14 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Capecitabine
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00130507
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-07-25
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** A new alternative treatment caused the decrease in the rhythm of recruitment.
- **Last updated:** 2019-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00130507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00130507, "Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00130507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*